Bausch + Lomb Co. (NYSE:BLCO) Receives $20.58 Consensus Target Price from Analysts

Bausch + Lomb Co. (NYSE:BLCO) has been given an average rating of “Hold” by the thirteen brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $20.58.

Several equities research analysts have commented on BLCO shares. HC Wainwright restated a “buy” rating and set a $23.00 target price on shares of Bausch + Lomb in a research report on Thursday, December 12th. Wells Fargo & Company upped their target price on shares of Bausch + Lomb from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Thursday, October 31st. Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a research report on Thursday, October 31st. Royal Bank of Canada upped their price target on Bausch + Lomb from $20.00 to $23.00 and gave the stock an “outperform” rating in a report on Tuesday, October 22nd. Finally, Stifel Nicolaus lifted their price objective on Bausch + Lomb from $16.00 to $19.00 and gave the stock a “hold” rating in a report on Monday, September 23rd.

Bausch + Lomb Stock Up 0.9 %

Shares of Bausch + Lomb stock opened at $18.06 on Friday. Bausch + Lomb has a one year low of $13.16 and a one year high of $21.69. The company has a market cap of $6.36 billion, a P/E ratio of -17.20, a PEG ratio of 1.74 and a beta of 0.47. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57. The firm has a fifty day moving average of $19.08 and a two-hundred day moving average of $17.88.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.01. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The firm had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the prior year, the company posted $0.22 earnings per share. The firm’s revenue for the quarter was up 18.8% on a year-over-year basis. On average, analysts forecast that Bausch + Lomb will post 0.6 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC acquired a new position in Bausch + Lomb in the second quarter valued at $173,000. Polar Asset Management Partners Inc. purchased a new position in shares of Bausch + Lomb during the 3rd quarter worth about $289,000. Gordian Capital Singapore Pte Ltd acquired a new stake in shares of Bausch + Lomb in the third quarter worth approximately $289,000. Verition Fund Management LLC purchased a new stake in Bausch + Lomb in the third quarter valued at approximately $302,000. Finally, XTX Topco Ltd acquired a new position in Bausch + Lomb during the third quarter worth approximately $309,000. 11.07% of the stock is currently owned by institutional investors and hedge funds.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.